

The monthly European Industrial Pharmacists' newsletter • February 2021



## Technology & Production

### The socio-economic impact of IMI1 projects

The Clarivate's Centre for Innovation in Regulatory Science analysed how the outcomes of 44 IMI1 projects impacted on four different areas relevant to Europe's socio-economic growth: innovation, manufacturing, R&D infrastructures and dissemination of information

[Read more...](#)



## Regulatory

### ICH's reflection paper and consultation on patient focused drug development

The document discusses how to better include the patients' perspective into drug development. The public consultation on the Reflection paper is open up to 7 March 2021; it may be followed by the issuing of new ICH's guidelines aimed to harmonise at the global level the approach used to capture patients' point of view on the ongoing development activities

[Read more...](#)



## Politics & Business

### A report on the impact of biosimilar competition in Europe

A white paper published by IQVIA discusses the many factors affecting the impact of biosimilars, from price policies to IP protection strategies. The document also proposes a set of KPIs useful to better assess this relevant sector, and offers a detailed analysis of many biosimilars already present in the European market and medicines close to reach patent expiry

[Read more...](#)



## Focus on EU's Countries

### Human and veterinary medicines: EMA's highlights of 2020

The European Medicines Agency approved last year 97 new human medicines and 20 veterinary ones. Many products are based on new active substances and innovative approaches to therapy. All achieved outcomes are described in the yearly reports published by the Agency

[Read more...](#)



## EIPG

### EIPG: Q&A follow up webinar session on MDR – Joint Statement on future modifications to the Directive on the RPQ for Pharmacists

Dr. Deavin has kindly offered to provide a 10–15-minute summary of the Regulations, followed by a Question-and-Answer session on 9th March 2021 as there were a large number of participants who were unable to join the webinar on 3rd of February and insufficient time to answer a number of questions. A Joint Statement on future modifications to the Directive on the Recognition of Professional Qualifications has been discussed at length with our European partners

[Read more...](#)